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Heart attacks comprise one of the main causes of death in the USA. A main adverse                                 
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category of injury is necrosis. Mounting evidence implicates electron transfer (ET), reactive                       
oxygen species (ROS) and oxidative stress (OS) as important factors in cardiovascular diseases.                         
In the generation of ROS, many in vivo enzymes are involved, in addition to exogenous agents.                               
Less attention has been paid to ET functions as the source of ROS. Participation of OS is                                 
supported by beneficial effects of antioxidants, but not in all cases. It should be recognized that                               
reaction mechanism is often multifaceted. 
Key words: cardiovascular diseases, reactive oxygen species, oxidative stress, toxicity,                   
antioxidants, arrhythmia 




Atherosclerosis is the leading cause of death world wide, representing one­third of total                           
deaths in the industrial countries. In the USA, coronary atherosclerosis, cerebrovascular                     
artherosclerosis and other cardiovascular diseases cost the health care providers billions of                       
dollars annually [1­3].Based on global trends, the World Health Organization projects that, by                         
2020, approximately half of all deaths in developed countries will be due to cardiovascular                           
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In the past several decades, a plethora of evidence implicates oxidative stress (OS)                           
as a mechanism with a central role in the pathogenesis of varieties of diseases and toxicities,                               





OS is a result of reactive oxygen species (ROS) and reactive nitrogen species (RNS)                             
produced within the cell endogenously by various enzymes or influenced by exogenous                       
materials. The most potent of the ROS/RNS are the free radical species, which have an unpaired                               
electron and capable of reacting with most of molecules by abstraction or insertion. These free                             
radical reactions can bring about permanent changes to the molecular structures of compounds                         
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Of all these reactive species, hydroxyl radical appears to be the most potent. This                             
radical, produced from superoxide anion radical generated by enzymes, reacts at a                       
diffusion­controlled rate with almost all adjacent molecules in the living cells. Fortunately, the                         
migrating ability of this species is limited. On the other hand, reactive H2O2 which is a                               
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very diffusible within and between cells causing oxidative damage to molecules in its path. This                             
property makes hydrogen peroxide an excellent cell signaling agent.  
Another aspect of mobility of these ROS and RNS is the subject of electron transfer                               
(ET) agents, which has received limited attention in the literature over the years. The electron in                               
motion is a charged entity which is accompanied by an electrical field which could play a role.                                 
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These ET agents bearing the single electron can diffuse through cells to sites                           
away from where they were generated and have the ability to create more ROS and RNS at a                                   
new site. Evidence also suggests that the ROS could behave as intercellular signaling                         
molecules. The present review mainly presents the most recent literature in relation to ROS,                           
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in addition to their extensive involvement in cardiovascular diseases. There is extensive                       
literature documenting the prevention or amelioration of harmful OS by AOs. On the other                           
hand, conflicting data exist.  
Sources of ROS and their role in cardiovascular disease  
A variety of enzymatic and non­enzymatic sources of ROS exists in blood                         
vessels. Hence, ROS and RNS produced by these sources play a crucial role in the functioning of                                 
vascular physiology of cardiovascular disease (Fig. 3). The main ROS and RNS produced in the                             
vessel walls are superoxide radical anion (O2•‾ ), hydrogen peroxide (H2O2), hydoxyl radical                         
(OH•) and nitric oxide (NO•). A plethora of evidence exists for the involvement of ROS/RNS in                               
CVD, such as atherosclerosis, hypertension, and ischemia, as set forth in this review and prior                             
ones referenced herein [7­13]. 
Enzymes within the cell are primary sources of ROS/RNS. Superoxide is produced by                           
one electron reduction of oxygen by several different enzymes, such as NAD (P) H oxidase,                             
xanthine oxidase, cyclooxygenase and cytochrome P450 within the cell (Fig. 3). In addition to                           
these, a number of external mediators also contribute to the ROS generation, such as ionizing                             
radiation, heavy metals, like Hg, Pb, Cd, Cr, Fe and Cu, metal­complexes, nano­particles,                         





Copyright owned by authors  |  Published by iMedPub 
7 
 
Open Journal of Medicine 







An important non­enzymatic source of ROS is the mitochondrion. The electron                       
carriers NADH and FADH2 situated in the inner mitochondrial membrane assist the oxidative                         
phosphorylation of ATP and superoxide generation. Evidence shows that the lack of oxygen                         
supply by either hypoxia or ischemia disrupts the mitochondrial electron transport chain,                       
resulting in ATP depletion, overload of Ca2+, membrane depolarization and cell death [7, 14].                           
Experimental models involving ischemia/reperfusion or hypoxia in vivo and vitro, suggested that                       
injury in the myocardium is caused by ROS from mitochondrial respiration [7, 14]. A small                             
amount of electron leak from the transport chain leads to superoxide via reaction with oxygen                             
[15]. 
Xanthine oxidase (XO) 
XO enzyme is involved in the purine degradation pathway. The reaction generates                         
uric acid and superoxide. The enzyme is localized in the plasma, endothelial cells, liver and the                               
small intestine. Excess ROS production, during hypoxia, enhances XO release into the plasma.                         
The significant increased XO activity in the vascular tissue leads to endothelial dysfunction in                           
hypercholestrerolemic rabbits and atherosclerotic humans; allopurinol or oxypurinol improved                 
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NADPH oxidase is a multi­subunit enzyme that catalyzes superoxide production.                     
Found in phagocytic cells, it plays a major role via superoxide in host defense against infection.                               
The NAD(P)H oxidases also include the NOX family of enzymes. NADH/NADPH oxidase                       
induces the formation of superoxide production in all types of cells in the vasculature,                           
endothelium, smooth muscle, and adventitia [7]. A study showed that angiotensin II induced                         
superoxide formation through NADH/NADPH in the vasculature leading to AngII­induced                   
hypertrophy and endothelial dysfunction [7]. The oxidation of LDL is well described in                         
artherosclerosis and a number of enzyme systems including NADPH and mitochondria are                       
involved in this process [9]. A recent study showed that ROS produced by NADPH oxidases and                               
NOX enzymes have a role in the endothelial dysfunction, inflammation, hypertrophy, apoptosis,                       
migration, fibrosis and angiogenesis [10]. NOX family of NAD(P)H oxidases has been                       
implicated in many forms of hypertension [11, 12]. 
A new vascular peroxidase 1 (VPO1) has been recently identified as a member of the                               
peroxidase family. VOP1 utilizes NOX­derived H2O2 to produce hypochlorous acid, a strong                       
oxidant which promotes OS [16]. NOX/VOP1 pathway­mediated OS plays an important role in                         
myocardial ischemia­reperfusion injury, endothelial apoptosis and smooth muscle proliferation.  
Nitric oxide synthase (NO) 
Another source of superoxide is nitric oxide synthase, which is a cytochrome P450                           
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L­arginine to form NO. However, under certain circumstances, the uncoupling of this enzyme                         
can lead to O2 reduction and the production of superoxide. Impairment of the vascular                           
endothelium is caused by disruption of the protective NO signaling pathway, which results in                           
decreased relaxation responses of blood vessels and vascular wall thickening and prothrombotic                       
state, leading to endothelial dysfunction [13]. Increased ROS production reduces the                     
bioavailabilty of NO, resulting in vasoconstriction, platelet aggregation and adhesion of                     
neutrophils to the endothelium [8]. NO also reacts with superoxide anion at diffusion­limited                         
rates to form the potent ONOO,־ which can lead to lipid, protein and nucleic acid oxidation.                               
Experimental data indicated peroxynitrite impaired vascular function and decreased cardiac                   
performance [7]. Other examples of NO involvement in CVD are presented in a 2001 review [7].  
Myeloperoxidase 
This enzyme, produced by activated phagocytes, uses H2O2 for the production of                         
more powerful oxidative substances. The enzyme is involved in NO consumption, modification                       
of LDL by oxidation and reaction with L­arginine for the production of NO synthase inhibitors.                             
This enzyme through NAD(P)H interaction forms HOCl which leads to atherosclerotic lesions                       
[8].   
Lipoxygenases 
These enzymes are involved in creating biologically active lipids, such as                       
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A review deals with oxygen, OS and hypoxia, in connection with heart failure [17].                             
The article details ROS in relation to ischemic syndrome, lipotoxicity, ion channels and calcium                           
flux. Another recent review highlights the importance of ROS in vascular biology and focuses on                             
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role in OS­induced elevated blood pressure [18]. Smoking and alcohol consumption were shown                         
to increase lipid peroxidation and cellular damage in coronary, artery disease patients [19]. A                           
review deals with lipid biosynthesis and its implications on cardiovascular disease [20].                       
Atherosclerosis is a progressive multifaceted inflammatory disease affecting large­ and                   
medium­sized arteries. Typically, this involves the formation and build­up of atherosclerotic                     
plaques by vascular degradation. A review deals with the elastin­driven degradation and its                         
signaling pathways [21]. Degradation of native elastin, the main extracellular matrix protein                       
responsible for resilience and elasticity of arteries, leads to the production of elastin­derived                         
peptides. These peptides have been proposed to participate in LDL oxidation and calcification of                           
the vascular wall.  
A recent review summarizes the status of redox­sensitive signaling in brain Ang                         
II­dependent cardiovascular diseases, hypertension and heart failure [22]. Data suggest increased                     
OS and decreased membrane fluidity in erythrocytes of coronary artery disease [23]. 
A study revealed that OS and high­density lipoprotein cholesterol are associated                       
with coronary artery calcification in patients with rheumatoid arthritis [24]. 
Blocking aldosterone receptors in patients with cardiovascular diseases reduced their                     
mortality [25]. The observation of reduced NO bioavailability in hyperaldosteronism and NF­kβ                       
activation implied the generation of OS by aldosterone. Data suggest that increased flux via                           
aldose reductase in diabetic increases injury after myocardial infarction, accelerates                   
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Increased ROS have been proposed as a possible cause of cardiac dysfunction in diabetic                           
patients. A report suggests activation of Ca2+/calmodulin­dependent protein kinase II induced by                       
impaired intracellular Ca2+ metabolism may stimulate ROS production in the diabetic heart [27].                         
Rho­kinase plays a critical role in various cellular functions. Mitogen p38­activated protein                       
kinase is involved in the inflammatory cytokine response to immune challenge. Findings suggest                         
Rho­kinase and p38 MAPK pathways may play a major function in ventricular hypertrophy [28]. 
Reactive Oxygen Species and Oxidative Stress: Recent Reports 
There is extensive literature linking ROS­OS with various cardiovascular                   
diseases. This section deals with reports from part of 2013. Some studies dealing with ROS­OS                             
can be found in the AO section. Many of the cardiovascular diseases, such as atherosclerosis,                             
heart failure and hypertension are linked to enhanced levels of ROS, and decreased AO function                             
[29]. The review emphasizes involvement of OS in cardiovascular illness. In heart failure, data                           
indicate a connection between OS and the cardiac operation in heart failure [30]. A vital role is                                 
played by kinases oxidant sensing and signaling which are connected to phosphorylation [31].                         
Redox regulation by kinases is involved in cardiovascular operation. Hypoglycemia and diabetes                       
are both related to cardiovascular malfunction [32]. Various pathways play a role, all of which                             
are related to ROS. The ROS damage cellular constituents and modulate cell signaling.                         
Hyperglycemia can lead to OS and endothelial dysfunction which play central roles in vascular                           
diseases. OS brings about changes in vascular cells. There is involvement of ROS in                           
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in the diabetic cardiovascular afflictions. In a related report, the widespread occurrence of                         
cardiovascular disease among diabetic patients indicates participation of OS [33]. The review                       
addresses the role of sirtuins in modulating proteins related to signaling and OS. Evidence                           
indicates an association of OS and the mitochondria with heart failure [34]. Myeloperoxidase                         
plays a role in cardiovascular disease via OS and inflammation [35]. The heme protein yields                             
oxidant products which play a role in the immune system. Nickel­induced OS and resulting                           
inflammation are crucial aspects in variability of heart rate [36]. Sleep apnea appears to be                             
involved with cardiovascular problems, including stroke, heart failure and arterial hypertension                     
[37]. These conditions appear to involve OS and inflammation. The OS appears to arise from                             
NADPH oxidase and other enzymes that generate ROS. Inside cardiomyocytes, ROS/RNS and                       
autophagy have pathological influences [38]. Cross talk between the two aspects occurs within                         
cardiovascular illness. Mitochondria are also involved in OS in cardiomyocytes. The                     
complicated interplay is involved in many pathologies, including those in the cardiovascular                       
system. Evidence supports an important relationship between obesity and cardiovascular illness                     
[39]. Certain proteins and kinases are also involved in regulating OS and redox levels. Possible                             
therapeutic aspects are addressed. A study was made of OS and damage to DNA in patients with                                 
heart failure and circulating blood leucocytes [40]. The implanted patients showed increased OS                         
and damage to DNA. A growing health problem worldwide is presented by cardiovascular                         
disease [41]. Extensive evidence points to OS as a key factor. The review addresses therapy                             
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cardiovascular pathology [42]. Activation of AO responsive signaling pathways protects                   
constituents from oxidative damage. MG 132 (tripeptide derived from amino acid leucine) is a                           
drug that prevents cardiovascular damage. Various vascular diseases are influenced by OS [43].                         
Enhanced ROS is importantly involved in cardiovascular pathology. The review discusses                     
involvement of RNAs in ROS production with participation vascular illnesses in which redox                         
imbalance plays a role.  
 
A long chain hydroxyl unsaturated carboxylic acid enhances generation of superoxide                       
which aggravates myocardial injury induced by ischemia­reperfusion [44]. In a study of                       
hypobasic hypoxia, there exists regulation of ROS and NO which is controlled by AO proteins                             
[45]. Low high­density lipoprotein is linked to enhancement of lipid peroxidation as a                         
mechanism associated with enhanced cardiovascular disease [46]. A report deals with signaling                       
by ROS in cardiovascular injury, together with the influence of AOs [47]. Zinc levels are linked                               
to inflammation and lipid peroxidation in heart disease [48]. In treatment of patients suffering                           
from myocardial infarction, attention should be paid to the harmful effects of oxidation products,                           
such as peroxides and aldehydes [49].  
An article deals with the role of angiotensin (Ang) in OS and ROS in cardiovascular                               
diseases. The action mode entails NADPH oxidases that generate ROS, with similar action from                           
mitochondria [50]. A related report discusses the critical role of mitochondrial ROS in heart                           
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AOs may be helpful. Excessive Ang is a factor in cardiovascular pathology [52]. The Ang                             
properties may reflect involvement of ROS and redox signaling. AOs are helpful in the                           
Ang­induced heart pathologies. A study deals with OS and inflammation in patients with                         
cardiovascular problems [53]. Hypertension, which is related to OS, is well established as a                           
contributor to cardiovascular illness [54]. In a study with the rat heart during aging, various ET                               
sites in mitochondria were found to increase ROS production and oxidative destruction [55].                         
Heart transplant patients demonstrate reduced OS after everolimus therapy [56]. Data indicate                       
that lower SOD and high uric acid may be linked to cardiovascular death in hemodialysis [57].                               
Hypothyroidism produces OS in the heart which is countered during pregnancy [58]. Data show                           
that ROS control various processes connected to cardiac functioning by various networks of                         
genes [59]. An investigation deals with changes during aging involving OS and energetics in the                             
hippocampus and heart of rats [60]. Possible therapy for cardiovascular illness was addressed                         
involving OS and inhibition of NO synthase [61]. A review puts focus on OS in the                               
cardiovascular system and CNS with emphasis on disease associated with aging [62].                       
Tocotrienol reduces OS in the heart and AO homocysteine in the plasma in rats [63]. Evidence                               
supports participation of OS, including inflammation, in atherosclerosis [64]. In kidney                     
malfunction, dislipidemia plays a role in impairment of OS, cardiovascular disease and                       
inflammation [65]. OS was found to play a role in cardiovascular illnesses in the obese [66].                               
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vascular peroxidase 1 as a promotor of OS in the cardiovascular system [16]. Data demonstrate a                               
role for OS in obesity [68].   
Antioxidants   
The prior sections present extensive data supporting an important role of ROS­OS                         
in cardiovascular illnesses. It is not surprising to find widespread evidence for prevention or                           
amelioration by AOs. The literature covered is from 2012 and part of 2013. Some AO material is                                 
also present in the ROS­OS section. Prior reviews present beneficial effects of AOs, as well as                               
disappointing results. The imbalance between ROS/RNS and AOs lead to OS when the former                           
predominate. Cells manifest potent AO defenses against ROS through enzymes, such as                       
superoxide dismutase (SOD), catalase and glutathione peroxidase (GSH) [69]. External sources                     
of AO supplementation, such as vitamin E, C, flavonoids, phenols and carotenes, can also                           
suppress the ROS [70]. 
Vitamin and antioxidant supplements were shown to prevent CVD through                     
suppression of OS [71]. α­Tocopherol acts as an AO to alleviate methotrexate­induced OS in rat                             
heart [72]. A study revealed intake of diet with high total AO capacity has preventive effects on                                 
CVD risk [73]. Resveratrol and other stilbene derivatives were shown to modulate NO                         
bioavailability during OS [74]. 
In diabetic cardiomyopathy animal models, cobalt­protoporphyrin treatment               
improved both cardiac function and coronary flow by inhibiting OS, and restoring eNOS/iNOS                         
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report deals with antioxidant enzymes as potential targets in cardioprotection and treatment of                         
CVDs [76]. Extracellular superoxide dismutase showed protective action against development of                     
atherosclerosis, hypertension, and heart failure involving in vivo experiments.  
In a clinical investigation involving patients with coronary heart disease and                       
dyslipidemnia, treatment with atorvastatin exerted antioxidative effects in 90% of the patients                       
and it normalized parameters of lipid peroxidation [77]. Rat models with myocardial infarction                         
on a diet of soy protein showed increased antioxidant enzyme activity and lower lipid                           
peroxidation [78]. Diet rich in olive oil phenolics was shown to prevent OS in the heart of mice                                   
by modulating Nrf2­dependent gene expression [79]. LDL­oxidation plays a key role in                       
pathogenesis of atherosclerosis and cardio vascular heart diseases through the initiation of plaque                         
formation. Lycopene was shown to act as an AO in decreasing this effect [80]. Interleukin­33                             
(IL­33) has been linked to chronic heart failure in animal studies. Serum levels of interleukin­33                             
were elevated in chronic heart failure patients whereas its activity was reduced [81]. Authors                           
suggest IL­33 may exert AO effects. 
Epidemiological studies with large numbers of men, women and diverse populations                       
have been supportive of the hypothesis that AOs prevent artery disease, peripheral vascular                         
disease, and other CVD­related disease through the prevention of low density lipoprotein                       
oxidation. However, interventional trials have been controversial, with some positive findings,                     
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interventional studies with carefully chosen populations, such as those under high levels of OS,                           
have yielded largely positive results [82].  
Evidence points to prevention by edaravone which could lead to therapy for heart                           
failure, and atherosclerosis, among other illnesses, arising from OS or apoptosis [83]. The                         
compound guards against inflammation and ischemia in the heart. The targets may be radicals in                             
these diseases since edaravone is well known as scavenger of radicals. The potent AO provides                             
neuroprotection in brain ischemia and other cardiovascular dysfunction. Apocynin ameliorates                   
atherosclerosis, apparently by countering superoxide [84]. The AO is a member of the phenol                           
class which is well known to exhibit AO properties [ 70]. Drugs that posses AO properties are                                 
used in treating cardiovascular illnesses [85]. This class demonstrates better success than those                         
with similar receptor affinity, but lacking AO action.  
Cardiovascular illness is the main cause of disease and death globally [86]. Evidence                           
supports involvement of ROS in the adverse conditions, contributing to aatherosclerosis and                       
diabetes. Involvement of OS in vascular disease is buttressed by data illustrating the therapeutic                           
effect of AOs. Addition of the AOs vitamins C and E to the diet decreased the prevalence of                                   
arterial disease [87]. Vitamin E also elicited a positive effect in combating cardiac                         
ischemia­reperfusion injury. Thus, alleviation of OS appears ro exert beneficial, cardiovascular                     
effects. However, controversy exists concerning the protection provided by vitamin E.  
Flavonoids, prevalent in healthy diets, are polyphenols that display AO properties and                         
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reduces inflammation and counters adverse mitochondrial OS [88]. Inflammation is associated                     
with the presence of ROS. The flavonoid lessened apoptosis by opposing production of ROS.                           
Mechanistic aspects of flavonoid AO action have been addressed [70]. Heart failure is                         
appreciably increased by diabetes [89]. Diabetic cardiomyopathy is linked to advanced glycation                       
end products (AGEs) which give rise to OS. In rats, diabetes produce cardiac changes associated                             
with OS and inflammation which are mediated by glyoxalase.  
Ginger has been used in folk medicine to treat cardiovascular diseases, including                         
hypertension [90]. A possible mechanism entails opposition to lipid peroxidation, which may be                         
associated with the AO properties of the polyphenol (related to vitamin E). In a related article,                               
wild blueberries which are replete with polyphenols, such as flavonoids, anthocyanins and                       
phenolic acids, are used in countering cardiovascular diseases [91].  
Arrhythmia  
This cardiac condition involves irregular heartbeat in which the electrical activity is                         
abnormal, either too fast or too slow. The seriousness can vary from minor to life threatening.                               
Antiarrhythmic drugs are available to treat the condition.  
Supplementation of fish oil in animals was found to lessen vulnerability of the heart                             
to arrhythmia induced by ischemia­reperfusion [92]. Desferrioxamine provides protection against                   
the heart condition, and is known to posses AO properties [93]). Exposure to particulate matter                             
(PM) in vivo and in vitro produced ventricular arrhythmia [94]. Introduction of PM induced ROS                             
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by kinase. Carbon monoxide was found to increase arrhythmia after stress [95]. The OS changed                             
Ca homeostasis. The end result could be rapid death. The drug carvediol appears to inhibit                             
arrhythmia in rabbits possessing cardiomyopathy [96]. The effect may be associated with a                         
decrease in ROS.   
Conclusion 
Cardiovascular diseases pose a serious threat worldwide. Knowledge at the basic,                       
molecular level concerning cause and prevention should aid in measures to prevent and cure.                           
Extensive literature demonstrates involvement of ROS and OS in the diseases. There is scant                           
recognition that ET agents play an important role in ROS formation. Although extensive reports                           
support prevention or allevation by AOs, other studies proved disappointing. More data                       
concerning fundamental aspects are needed from future research. A prior review in 2005                         
provides the involvement of ET­ROS­OS in the mechanism of cardiovascular toxins [97]. The                         
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